Results from a 36-Week Open-Label Study of Recombinant Human Growth Hormone and Testosterone in Facioscapulohumeral Muscular Dystrophy (FSHD)

被引：0
|
作者：
Heatwole, Chad [1 ]
Luebbe, Elizabeth [1 ]
Hamel, Johanna [1 ]
Mongiovi, Philip [1 ]
Ciafaloni, Emma [1 ]
Dilek, Nuran [1 ]
Martens, William [1 ]
Weber, David [2 ]
Hani, Rashid [1 ]
Allen, Jamie [1 ]
Smith, Claire [1 ]
Howell, Samantha [1 ]
Rosero, Spencer [1 ]
Eichinger, Katy [1 ]
Baker, Linday [1 ]
Dekdebrun, Jeanne [1 ]
Hilbert, Jim [1 ]
Varma, Anika [1 ]
McDermott, Michael [1 ]
Thornton, Charles [1 ]
Moxley, Richard [1 ]
机构：
[1] Univ Rochester Med Ctr, Rochester, NY USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202958
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S48.009
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Safety of a Novel Gel Formulation of Clindamycin Phosphate 1.2%-Tretinoin 0.025%: Results From a 52-Week Open-Label Study
    Kircik, Leon H.
    Pereclo, Marina I.
    Bucko, Alicia D.
    Loss, Robert W., Jr.
    Fowler, Joseph F., Jr.
    Wortzman, Mitchell
    Neumaier, George J.
    CUTIS, 2008, 82 (05): : 358 - 366
  • [32] Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study
    Dougados, Maxime
    Braun, Jurgen
    Szanto, Sandor
    Combe, Bernard
    Geher, Pal
    Leblanc, Veronique
    Logeart, Isabelle
    RHEUMATOLOGY, 2012, 51 (09) : 1687 - 1696
  • [33] Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
    Rajnish Mago
    Giovanna Forero
    William M. Greenberg
    Carl Gommoll
    Changzheng Chen
    Clinical Drug Investigation, 2013, 33 : 861 - 861
  • [34] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
    Hisamitsu Ishihara
    Susumu Yamaguchi
    Ikko Nakao
    Seitaro Asahina
    Taishi Sakatani
    Diabetology International, 2019, 10 : 37 - 50
  • [35] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
    Ishihara, Hisamitsu
    Yamaguchi, Susumu
    Nakao, Ikko
    Asahina, Seitaro
    Sakatani, Taishi
    DIABETOLOGY INTERNATIONAL, 2019, 10 (01) : 37 - 50
  • [36] LONG-TERM PULMONARY FUNCTION OUTCOMES IN NON-AMBULATORY PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY TREATED WITH ATALUREN: 240-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY
    McDonald, Craig M.
    Campbell, Craig
    Mercuri, Eugenio
    Muntoni, Francesco
    Selby, Kathryn
    McIntosh, Joseph
    Bibbiani, Francesco
    Trifillis, Panayiota
    Souza, Marcio
    Peltz, Stuart W.
    Tulinius, Mar
    MUSCLE & NERVE, 2018, 58 : S12 - S12
  • [37] Role of recombinant human growth hormone in weaning of prolonged ventilation after major abdominal cancer surgeries; open-label, placebo-controlled, randomized trial
    Shaker, Ehab Hanafy
    Kamel, Mahmoud Ahmed
    ANAESTHESIA PAIN & INTENSIVE CARE, 2022, 26 (02) : 175 - 181
  • [38] Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study
    Castro, Diana
    Finkel, Richard S.
    Farrar, Michelle A.
    Tulinius, Mar
    Krosschell, Kristin J.
    Saito, Kayoko
    Gambino, Giulia
    Foster, Richard
    Bhan, Ishir
    Wong, Janice
    Kandinov, Boris
    Farwell, Wildon
    NEUROLOGY, 2020, 94 (15)
  • [39] Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study
    Finkel, R.
    Castro, D.
    Farrar, M.
    Tulinius, M.
    Krosschell, K.
    Saito, K.
    Gambino, G.
    Foster, R.
    Ramirez-Schrempp, D.
    Wong, J.
    Kandinov, B.
    Farwell, W.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S124 - S124
  • [40] Bone Turnover in Patients With Hypoparathyroidism Treated for 5 Years With Recombinant Human Parathyroid Hormone, rhPTH(1-84), in the Open-Label RACE Study
    Mannstadt, Michael
    Bilezikian, John P.
    Bone, Henry
    Clarke, Bart L.
    Denham, Douglas
    Levine, Michael A.
    Peacock, Munro
    Rothman, Jeffrey
    Shoback, Dolores M.
    Vokes, Tamara J.
    Warren, Mark L.
    Watts, Nelson B.
    Lee, Hak-Myung
    Sherry, Nicole
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 128 - 129
12345